Tag: AbbVie Inc (ABBV)

AbbVie Inc to Acquire ImmunoGen

AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. ( ABBV ) and ImmunoGen ( IMGN ) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug...

Read More

November 30, 2023

0

Regenxbio and AbbVie Inc Agreement. See Also: Gilead Sciences and Everest Medicines News

Regenxbio and AbbVie Inc Agreement Regenxbio ( RGNX ) announced the successful closure of the collaboration and license agreement with AbbVie Inc ( ABBV ) for the development and commercialization of RGX-314, a potential one time gene therapy for wet...

Read More

November 12, 2021

0

AbbVie Inc's Two Different, Yet, Positive Impacting News 

AbbiVie Inc's Acquisition and Approval 1. AbbVie's Acquisition    AbbVie Inc. ( ABBV ) and Landos Biopharma, Inc . ( LABP ) announced a definitive agreement under which AbbVie will acquire Landos Biopharma, a clinical stage biopharmaceutical firm  focused on...

Read More

March 26, 2024

0

An Important Milestone for Regenxbio Treatment of Wet AMD

Regenxbio Good News for wet AMD On January 10, 2022,   Regenxbio Inc. ( RGNX ) announced the initiation of ASCENT, the second of two Phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in...

Read More

February 8, 2022

0

AbbVie Inc's Two Different, Yet, Positive Impacting News 

AbbiVie Inc's Acquisition and Approval 1. AbbVie's Acquisition    AbbVie Inc. ( ABBV ) and Landos Biopharma, Inc . ( LABP ) announced a definitive agreement under which AbbVie will acquire Landos Biopharma, a clinical stage biopharmaceutical firm  focused on...

Read More

March 26, 2024

0

Bristol-Myers Squibb Combination Improving the Treatment of Metastatic Melanoma; AbbVie Improving the Treatment of Crohn's Disease

Offsetting the Biotech Firms' Good News There is no doubt that good news is filling the media about outperformances of both development-stage small biotech firms and revenues-generating firms. This good news has been offset by inflation, hiked interest rates, that...

Read More

July 29, 2022

0

For Migraine Patients and People Interested in New Migraine Results, AbbVie Inc is Published in The Lancet.  

AbbVie Inc UBRELVY Results Published in The Lancet AbbVie Inc ( ABBV ) announced detailed results  published in The Lancet  evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 mg for the acute treatment of migraine when administered during the prodrome...

Read More

November 17, 2023

0

AbbVie Inc to Acquire ImmunoGen

AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. ( ABBV ) and ImmunoGen ( IMGN ) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug...

Read More

November 30, 2023

0

AbbVie Inc's Two Different, Yet, Positive Impacting News 

AbbiVie Inc's Acquisition and Approval 1. AbbVie's Acquisition    AbbVie Inc. ( ABBV ) and Landos Biopharma, Inc . ( LABP ) announced a definitive agreement under which AbbVie will acquire Landos Biopharma, a clinical stage biopharmaceutical firm  focused on...

Read More

March 26, 2024

0

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0